A phase I trial of enzastaurin in patients with recurrent gliomas (Q33384375)

26 July 2017

A phase I trial of enzastaurin in patients with recurrent gliomas (English)

1 reference

26 July 2017

phase I clinical trial

0 references

author name string

Teri N Kreisl

1

1 reference

26 July 2017

Lyndon Kim

2

1 reference

26 July 2017

Kraig Moore

3

1 reference

26 July 2017

Paul Duic

4

1 reference

26 July 2017

Svetlana Kotliarova

5

1 reference

26 July 2017

Jennifer Walling

6

1 reference

26 July 2017

Luna Musib

7

1 reference

26 July 2017

Donald Thornton

8

1 reference

26 July 2017

Paul S Albert

9

1 reference

26 July 2017

Howard A Fine

10

1 reference

26 July 2017

language of work or name

English

0 references

publication date

5 May 2009

1 reference

26 July 2017

Clinical Cancer Research

1 reference

26 July 2017

15

1 reference

26 July 2017

10

1 reference

26 July 2017

3617-3623

1 reference

Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531.

26 July 2017

1 reference

12 December 2020

Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation

1 reference

12 December 2020

Targeting protein kinase C: new therapeutic opportunities against high-grade malignant gliomas?

1 reference

12 December 2020

Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer

1 reference

12 December 2020

Clinically relevant drug interactions with antiepileptic drugs

1 reference

12 December 2020

PKC-eta mediates glioblastoma cell proliferation through the Akt and mTOR signaling pathways

1 reference

12 December 2020

Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway

1 reference

12 December 2020

Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning

1 reference

12 December 2020

Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors

1 reference

12 December 2020

Elevated protein kinase C betaII is an early promotive event in colon carcinogenesis.

1 reference

12 December 2020

Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis

1 reference

12 December 2020

(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta

1 reference

12 December 2020

Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor

1 reference

12 December 2020

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

12 December 2020

Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations

1 reference

12 December 2020

Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer

1 reference

12 December 2020

Protein kinase C betaII regulates Akt phosphorylation on Ser-473 in a cell type- and stimulus-specific fashion.

1 reference

12 December 2020

10.1158/1078-0432.CCR-08-3071

Identifiers

DOI

1 reference

26 July 2017

0 references

1 reference